•  
  •  
  •  
  •  

2025-10-24 04:25:25

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Sagar Cements Ltd reports consolidated loss of Rs. 42.31 crores in Q2FY26
  • PTC India Financial Services Ltd consolidated Q2FY26 net profit at Rs. 88.14 crores
  • The South India Paper Mills Ltd Q2FY26 PAT at Rs. 2.81 crore
  • CCAvenue Further Strengthens its Partnership with Ujjivan Small Finance Bank with White-Labelled Payment Gateway Solutions
  • SBI General Insurance Outpaces Industry with 10.7% Growth in H1FY26

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Laurus Labs Limited approves interim dividend of Rs. 0.80
  • Lilly and Cipla sign a distribution and promotion agreement for Yurpeak® in India
  • Caplin Steriles Ltd receives USFDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection
  • Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP
  • Advagen Holdings Inc. to acquire stake in GEn1E Lifesciences Inc.
  • Innova Captab Limited updates on SMDC inspection
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL
  • Veerhealth Care Limited receives order
  • NATCO Pharma Limited - Legal update regarding Risdiplam
  • Strides and Incepta Partner to Expand Women's Health Access with WHO-Prequalified Contraceptive
  • Welcure Drugs & Pharmaceuticals Ltd allots 11,23,58,200 Bonus Equity Shares
  • Novelix Pharmaceuticals Ltd signs Technology Transfer agreement GMBU e.V., Germany for Large-Scale of Astaxanthin
  • IOL Chemicals and Pharmaceuticals Ltd receives EDQM certificate for Pantoprazole Sodium Sesquihydrate Process-III
  • AstraZeneca Pharma India Ltd to launch Sodium Zirconium Cyclosilicate powder in Nov 2025
  • Relonchem Limited receives Marketing Authorization for two of its products
  • Coral Laboratories Ltd announces capacity expansion of Ointment Manufacturing
  • Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
  • Fredun Pharmaceuticals Ltd launches India's First Pure Jain Dog Biscuit
  • Lupin gets one observation from USFDA for Somerset, New Jersey manufacturing facility
  • Emcure Pharmaceuticals Ltd completes surveillance inspection by USFDA without any observation
  • Jubilant HollisterStier LLC launches New High-Speed Isolator based Line, at its Spokane Manufacturing Facility in the US
  • Legal update regarding Risdiplam - Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal
  • Fredun Pharmaceuticals Acquires Wagr.ai
  • Lupin unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • Sagar Cements Ltd reports consolidated loss of Rs. 42.31 crores in Q2FY26
  • PTC India Financial Services Ltd consolidated Q2FY26 net profit at Rs. 88.14 crores
  • The South India Paper Mills Ltd Q2FY26 PAT at Rs. 2.81 crore
  • CCAvenue Further Strengthens its Partnership with Ujjivan Small Finance Bank with White-Labelled Payment Gateway Solutions
  • SBI General Insurance Outpaces Industry with 10.7% Growth in H1FY26


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024